Altered eicosanoid metabolism in the cystic fibrosis mouse small intestine

Journal of Pediatric Gastroenterology and Nutrition

Volumn 47, Issue 4, 2008, Pages 406-416

  De Lisle, Robert C ^a   Meldi, Lauren ^a   Flynn, Maureen ^a   Jansson, Kyle ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Group V; Hydroxyeicosatetraenoic acid; Hydroxyprostaglandin dehydrogenase; Leukotriene B4 dehydrogenase; Phospholipase A2; Prostaglandin

Indexed keywords

12 HYDROXYDEHYDROGENASE; 15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 15 OXOPROSTAGLANDIN 13 REDUCTASE; ALKANE 1 MONOOXYGENASE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOCHROME P450; CYTOCHROME P450 2A10; CYTOCHROME P450 2C40; HYDROXYICOSATETRAENOIC ACID; ICOSANOID; LEUKOTRIENE B4; LEUKOTRIENE C4 SYNTHASE; MESSENGER RNA; OXIDOREDUCTASE; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE 1; PROSTAGLANDIN SYNTHASE 2; RIBOSOMAL PROTEIN L26; RIBOSOME PROTEIN; SECRETORY PHOSPHOLIPASE A2; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DOWN REGULATION; ENZYME IMMUNOASSAY; FATTY ACID BLOOD LEVEL; GENE EXPRESSION; ICOSANOID METABOLISM; KNOCKOUT MOUSE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMALL INTESTINE; UPREGULATION; WESTERN BLOTTING; WILD TYPE; ANIMAL; C57BL MOUSE; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; METHODOLOGY; MOUSE MUTANT;

ANIMALS; BLOTTING, WESTERN; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EICOSANOIDS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; IMMUNOHISTOCHEMISTRY; INTESTINE, SMALL; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 59649107604     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/mpg.0b013e31817e0f2c     Document Type: Article

References (70)

1. Balough K, McCubbin M, Weinberger M, et al. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol 1995;20:63-70.
2. Khan TZ,Wagener JS, Bost T, et al. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995;151: 1075-82.
3. Levistre R, Lemnaouar M, Rybkine T, et al. Increase of bradykininstimulated arachidonic acid release in a delta F508 cystic fibrosis epithelial cell line. Biochim Biophys Acta 1993;1181:233-9.
4. Bhura-Bandali FN, Suh M, Man SF, et al. The deltaF508 mutation in the cystic fibrosis transmembrane conductance regulator alters control of essential fatty acid utilization in epithelial cells. J Nutr2000;130:2870-5.
5. Andersson C, Zaman MM, Jones AB, et al. Alterations in immune response and PPAR/LXR regulation in cystic fibrosis macrophages. J Cyst Fibros 2008;7:68-78.
6. Anderson CM. Hypothesis revisited: cystic fibrosis: a disturbance of water and electrolyte movement in exocrine secretory tissue associated with altered prostaglandin (PGE2) metabolism? J Pediatr Gastroenterol Nutr 1984;3:15-22.
7. Lloyd-Still JD, Johnson SB, Holman RT. Essential fatty acid status in cystic fibrosis and the effects of safflower oil supplementation. Am J Clin Nutr 1981;34:1-7.
8. Carlstedt-Duke J, Bronnegard M, Strandvik B. Pathological regulation of arachidonic acid release in cystic fibrosis: the putative basic defect. Proc Natl Acad Sci USA 1986;83:9202-6.
9. Strandvik B, Gronowitz E, Enlund F, et al. Essential fatty acid deficiency in relation to genotype in patients with cystic fibrosis. J Pediatr 2001;139:650-5.
10. Freedman SD, Blanco PG, Zaman MM, et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med2004;350:560-9.
11. Li Y, Wang W, Parker W, et al. Adenosine regulation of cystic fibrosis transmembrane conductance regulator through prostenoids in airway epithelia. Am J Respir Cell Mol Biol 2006;34: 600-8.
12. Berguerand M, Klapisz E, Thomas G, et al. Differential stimulation of cytosolic phospholipase A2 by bradykinin in human cystic fibrosis cell lines. Am J Respir Cell Mol Biol 1997;17:481-90.
13. Medjane S, Raymond B, Wu Y, et al. Impact of CFTR dF508 mutation on prostaglandin E2 production and type IIA phospholipase A2 expression by pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol 2005;289:L816-24.
14. Miele L, Cordella-Miele E, Xing M, et al. Cystic fibrosis gene mutation (dF508) is associated with an intrinsic abnormality in Ca2+-induced arachidonic acid release by epithelial cells. DNA Cell Biol 1997;16:749-59.
15. Wilschanski M, Durie PR. Patterns of GI disease in adulthood associated with mutations in the CFTR gene. Gut 2007;56:1153-63.
16. McCool DJ, Marcon MA, Forstner JF, et al. The T84 human colonic adenocarcinoma cell line produces mucin in culture and releases it in response to various secretagogues. Biochem J 1990;267:491-500.
17. Isselbacher KJ. The role of arachidonic acid metabolites in gastrointestinal homeostasis. Biochemical, histological, and clinical gastrointestinal effects. Drugs 1987;33 (Suppl 1):38-46.
18. Bali A, Stableforth DE, Asquith P. Prolonged small-intestinal transit time in cystic fibrosis. BMJ (Clin Res Ed) 1983;287:1011-3.
19. Dalzell AM, Heaf DP. Oro-caecal transit time and intra-luminal pH in cystic fibrosis patients with distal intestinal obstruction syndrome. Acta Univ Carol [Med] (Praha) 1990;36:159-60.
20. Dalzell AM, Freestone NS, Billington D, et al. Small intestinal permeability and orocaecal transit time in cystic fibrosis. Arch Dis Child 1990;65:585-8.
21. Escobar H, Perdomo M, Vasconez F, et al. Intestinal permeability to 51Cr-EDTA and orocecal transit time in cystic fibrosis. J Pediatr Gastroenterol Nutr 1992;14:204-7.
22. Lewindon PJ, Robb TA, Moore DJ, et al. Bowel dysfunction in cystic fibrosis: importance of breath testing. J Paediatr Child Health1998;34: 79-82.
23. Murphy MS, Brunetto AL, Pearson AD, et al. Gut hormones and gastrointestinal motility in children with cystic fibrosis. Dig Dis Sci1992;37:187-92.
24. Gregory PC. Gastrointestinal pH, motility/transit, and permeability in cystic fibrosis. J Pediatr Gastroenterol Nutr 1996;23:513-23.
25. Fridge JL, Conrad C, Gerson L, et al. Risk factors for small bowel bacterial overgrowth in cystic fibrosis. J Pediatr Gastroenterol Nutr2007;44:212-8.
26. Husebye E. The pathogenesis of gastrointestinal bacterial overgrowth. Chemotherapy 2005;51 (Suppl 1):1-22.
27. SinghVV,ToskesPP.Small bowel bacterial overgrowth: presentation, diagnosis, and treatment. Curr Gastroenterol Rep 2003;5: 365-72.
28. De Lisle RC. Altered transit and bacterial overgrowth in the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol 2007;293:G104-11.
29. Norkina O, Burnett TG, De Lisle RC. Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine. Infect Immun 2004;72:6040-9.
30. Rosenberg LA, Schluchter MD, Parlow AF, et al. Mouse as a model of growth retardation in cystic fibrosis. Pediatr Res 2006;59:191-5.
31. Norkina O, Kaur S, Ziemer D, et al. Inflammation of the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol 2004;286:G1032-41.
32. Raia V, Maiuri L, De Ritis G, et al. Evidence of chronic inflammation in morphologically normal small intestine of cystic fibrosis patients. Pediatr Res 2000;47:344-50.
33. Smyth RL, Croft NM, O'Hea U, et al. Intestinal inflammation in cystic fibrosis. Arch Dis Child 2000;82:394-9.
34. Cesarone CF, Bolognesi C, Santi L. Improved microfluorometric DNA determination in biological material using 33258 Hoechst. Anal Biochem 1979;100:188-97.
35. 2α activation. Blood2007;110:561-7.
36. Nieves D, Moreno JJ. Hydroxyeicosatetraenoic acids released through the cytochrome P-450 pathway regulate 3T6 fibroblast growth. J Lipid Res 2006;47:2681-9.
37. Moreno JJ. Cyclooxygenase and cytochrome P-450 pathways induced by fetal calf serum regulate wound closure in 3T6 fibroblast cultures through the effect of prostaglandin E2 and 12 and 20 hydroxyeicosatetraenoic acids. J Cell Physiol 2003;195:92-8.
38. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002;82:131-85.
39. Nakagawa K, Holla VR, Wei Y, et al. Salt-sensitive hypertension is associated with dysfunctional Cyp4a10 gene and kidney epithelial sodium channel. J Clin Invest 2006;116:1696-702.
40. Muller DN, Schmidt C, Barbosa-Sicard E, et al. Mouse Cyp4a isoforms: enzymatic properties, gender-and strain-specific expression, and role in renal 20-hydroxyeicosatetraenoic acid formation. Biochem J 2007;403:109-18.
41. Tsao CC, Foley J, Coulter SJ, et al. CYP2C40, a unique arachidonic acid 16-hydroxylase, is the major CYP2C in murine intestinal tract. Mol Pharmacol 2000;58:279-87.
42. Capdevila JH. Regulation of ion transport and blood pressure by cytochrome p450 monooxygenases. Curr Opin Nephrol Hypertens2007;16:465- 70.
43. Wegmann M, Kampen A, Weber S, et al. Effect of hydroxyeicosatetraenoic acids on furosemide-sensitive chloride secretion in rat distal colon. J Pharmacol Exp Ther 2000;295:133-8.
44. Hori T, Yokomizo T, Ago H, et al. Structural basis of leukotriene B4 12-hydroxydehydrogenase/15-Oxo-prostaglandin 13-reductase catalytic mechanismand a possible Src homology 3 domain binding loop. J Biol Chem 2004;279:22615-23.
45. Silva PJ, Juengel JL, Rollyson MK, et al. Prostaglandin metabolism in the ovine corpus luteum: catabolism of prostaglandin F(2α) (PGF(2α)) coincides with resistance of the corpus luteum to PGF(2α). Biol Reprod 2000;63:1229-36.
46. Basu S. Novel cyclooxygenase-catalyzed bioactive prostaglandin F(2α) from physiology to new principles in inflammation. Med Res Rev 2006;27:435-68.
47. De Lisle RC, Roach E, Jansson K. Effects of laxative and N-acetylcysteine on mucus accumulation, bacterial load, transit, and inflammation in the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol 2007;293: G577-84.
48. Sawada H, Murakami M, Enomoto A, et al. Regulation of type V phospholipase A2 expression and function by proinflammatory stimuli. Eur J Biochem 1999;263:826-35.
49. Grossman EM, Longo WE, Mazuski JE, et al. Role of cytoplasmic and secretory phospholipase A2 in intestinal epithelial cell prostaglandin E2 formation. Int J Surg Invest 2000;1:467-76.
50. Satake Y, Diaz BL, Balestrieri B, et al. Role of group V phospholipase A2 in zymosan-induced eicosanoid generation and vascular permeability revealed by targeted gene disruption. J Biol Chem2004;279:16488-94.
51. Cui X, Kalsotra A, Robida AM, et al. Expression of cytochromes P450 4F4 and 4F5 in infection and injury models of inflammation. Biochim Biophys Acta 2003;1619:325-31.
52. Beigneux AP, Moser AH, Shigenaga JK, et al. Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response. Biochem Biophys Res Commun 2002;293:145-9.
53. Li-Masters T, Morgan ET. Effects of bacterial lipopolysaccharide on phenobarbital-induced CYP2B expression in mice. Drug Metab Dispos 2001;29:252-7.
54. Ivanov AI, Scheck AC, Romanovsky AA. Expression of genes controlling transport and catabolism of prostaglandin E2 in lipopolysaccharide fever. Am J Physiol Regul Integr Comp Physiol2003;284:R698-706.
55. Akiba Y, Furukawa O, Guth PH, et al. Sensory pathways and cyclooxygenase regulate mucus gel thickness in rat duodenum. Am J Physiol Gastrointest Liver Physiol 2001;280: G470-4.
56. Sbarbati A, Bertini M, Catassi C, et al. Ultrastructural lesions in the small bowel of patients with cystic fibrosis. Pediatr Res 1998;43: 234-9.
57. Ishizawa M. Contractile effects of 16-methyl analogues of PGE2 on the circular and longitudinal muscles of the guinea-pig isolated colon. Prostaglandins 1991;42:579-86.
58. Türler A, Schnurr C, Nakao A, et al. Endogenous endotoxin participates in causing a panenteric inflammatory ileus after colonic surgery. Ann Surg 2007;245:734-44.
59. Wang B, Glatzle J, Mueller MH, et al. Lipopolysaccharide-induced changes in mesenteric afferent sensitivity of rat jejunum in vitro: role of prostaglandins. Am J Physiol Gastrointest Liver Physiol2005;289:G254-60.
60. Meldi L, De Lisle RC. Impaired enteric circular muscle activity in the cystic fibrosis mouse small intestine: role of prostaglandin E2 [abstract]. Gastroenterology 2008;134 (Suppl 1):479.
61. Otani T, Yamaguchi K, Scherl E, et al. Levels of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement ofTNF-α.Am J Physiol Gastrointest Liver Physiol 2006;290: G361-8.
62. Backlund MG, Mann JR, Holla VR, et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem2005;280:3217-23.
63. Myung SJ, Rerko RM, Yan M, et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci USA 2006;103:12098-102.
64. Yan M, Rerko RM, Platzer P, et al. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-β-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci USA 2004;101:17468-73.
65. Pham H, Eibl G, Vincenti R, et al. 15-Hydroxyprostaglandin dehydrogenase suppresses K-Ras(V12)-dependent tumor formation in Nu/Nu mice. Mol Carcinogen 2008;47:466-77.
66. Beharry S, Ackerley C, Corey M, et al. Long-term docosahexaenoic acid therapy in a congenic murine model of cystic fibrosis. Am J Physiol Gastrointest Liver Physiol 2007;292:G839-48.
67. Neglia JP, FitzSimmons SC, Maisonneuve P, et al. The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group. N Engl J Med 1995;332:494-9.
68. Maisonneuve P, FitzSimmons SC, Neglia JP, et al. Cancer risk in nontransplanted and transplanted cystic fibrosis patients: a 10-year study. J Natl Cancer Inst 2003;95:381-7.
69. Bennett A, Hensby CN, Sanger GJ, et al. Metabolites of arachidonic acid formed by human gastrointestinal tissues and their actions on the muscle layers. Br J Pharmacol 1981;74:435-44.
70. Yamamoto T, Yokomizo T, Nakao A, et al. Immunohistochemical localization of guinea-pig leukotriene B4 12-hydroxydehydrogenase/ 15-ketoprostaglandin 13-reductase. Eur J Biochem 2001;268: 6105-13.